Healios K.K. (4593.T)
JPY 181.0
(1.69%)
JPY 181.0
(1.69%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -3 Billion JPY | 32.34% |
| 2022 | -4.51 Billion JPY | -30.78% |
| 2021 | -3.61 Billion JPY | 14.34% |
| 2020 | -3.96 Billion JPY | 9.84% |
| 2019 | -4.16 Billion JPY | 12.11% |
| 2018 | -5 Billion JPY | -116.42% |
| 2017 | -1.64 Billion JPY | 29.0% |
| 2016 | -3.23 Billion JPY | -238.92% |
| 2015 | -932.34 Million JPY | -104.77% |
| 2014 | -356.03 Million JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -249 Million JPY | 92.57% |
| 2024 Q1 | -974 Million JPY | 37.45% |
| 2023 Q4 | -1.15 Billion JPY | -97.26% |
| 2023 FY | - JPY | 32.34% |
| 2023 Q2 | -448 Million JPY | 19.57% |
| 2023 Q1 | -557 Million JPY | 38.25% |
| 2023 Q3 | -585 Million JPY | -30.58% |
| 2022 Q1 | -1.14 Billion JPY | -162.9% |
| 2022 Q4 | -902 Million JPY | -9.33% |
| 2022 FY | - JPY | -30.78% |
| 2022 Q3 | -825 Million JPY | 44.52% |
| 2022 Q2 | -1.48 Billion JPY | -30.32% |
| 2021 Q3 | -1.36 Billion JPY | -143.57% |
| 2021 FY | - JPY | 14.34% |
| 2021 Q1 | -830 Million JPY | 29.54% |
| 2021 Q2 | -560 Million JPY | 32.53% |
| 2021 Q4 | -434 Million JPY | 68.18% |
| 2020 FY | - JPY | 9.84% |
| 2020 Q4 | -1.17 Billion JPY | -14.81% |
| 2020 Q3 | -1.02 Billion JPY | -18.34% |
| 2020 Q2 | -867 Million JPY | 3.13% |
| 2020 Q1 | -895 Million JPY | 28.11% |
| 2019 FY | - JPY | 12.11% |
| 2019 Q2 | -1.01 Billion JPY | -6.48% |
| 2019 Q1 | -957 Million JPY | 6.54% |
| 2019 Q3 | -722 Million JPY | 29.15% |
| 2019 Q4 | -1.24 Billion JPY | -72.44% |
| 2018 Q4 | -1.02 Billion JPY | -41.05% |
| 2018 FY | - JPY | -116.42% |
| 2018 Q2 | -2.76 Billion JPY | -406.61% |
| 2018 Q1 | -545 Million JPY | 2.91% |
| 2018 Q3 | -726 Million JPY | 73.71% |
| 2017 Q1 | -518.46 Million JPY | -61.95% |
| 2017 Q4 | -561.33 Million JPY | 34.59% |
| 2017 Q2 | 191.65 Million JPY | 136.97% |
| 2017 Q3 | -858.19 Million JPY | -547.78% |
| 2017 FY | - JPY | 29.0% |
| 2016 Q1 | -2.12 Billion JPY | -498.21% |
| 2016 FY | - JPY | -238.92% |
| 2016 Q4 | -320.14 Million JPY | 28.06% |
| 2016 Q3 | -445.03 Million JPY | 13.13% |
| 2016 Q2 | -512.27 Million JPY | 75.87% |
| 2015 Q4 | -354.94 Million JPY | -61.31% |
| 2015 Q1 | -232.6 Million JPY | 0.0% |
| 2015 Q2 | -280.74 Million JPY | -20.7% |
| 2015 Q3 | -220.04 Million JPY | 21.62% |
| 2015 FY | - JPY | -104.77% |
| 2014 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 958.1 Million JPY | 413.85% |
| PRISM BioLab Co.,LTD | -488.13 Million JPY | -516.022% |
| GNI Group Ltd. | 14.48 Billion JPY | 120.754% |
| Linical Co., Ltd. | 1.24 Billion JPY | 341.094% |
| Trans Genic Inc. | 240.95 Million JPY | 1347.966% |
| MEDINET Co., Ltd. | -1.35 Billion JPY | -121.779% |
| Soiken Holdings Inc. | -583.2 Million JPY | -415.598% |
| Cytori Cell Research Institute, Inc. | -603.09 Million JPY | -398.598% |
| AnGes, Inc. | -8.86 Billion JPY | 66.061% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | -133.918% |
| Nxera Pharma Co., Ltd. | -7.39 Billion JPY | 59.359% |
| Immuno-Biological Laboratories Co., Ltd. | 128.1 Million JPY | 2447.257% |
| NanoCarrier Co., Ltd. | -863 Million JPY | -248.436% |
| Carna Biosciences, Inc. | -1.09 Billion JPY | -175.421% |
| CanBas Co., Ltd. | 53.65 Million JPY | 5704.742% |
| D. Western Therapeutics Institute, Inc. | -775.59 Million JPY | -287.704% |
| RaQualia Pharma Inc. | -111.8 Million JPY | -2589.6% |
| Chiome Bioscience Inc. | -1.21 Billion JPY | -148.156% |
| Kidswell Bio Corporation | -1.38 Billion JPY | -117.769% |
| PeptiDream Inc. | 7.37 Billion JPY | 140.767% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | -55.828% |
| Ribomic Inc. | -1.01 Billion JPY | -196.98% |
| SanBio Company Limited | -4.52 Billion JPY | 33.547% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | -157.938% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | -115.855% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | -114.479% |
| StemRIM | -2.03 Billion JPY | -47.982% |
| CellSource Co., Ltd. | 1.3 Billion JPY | 330.167% |
| FunPep Company Limited | -952 Million JPY | -215.861% |
| Kringle Pharma, Inc. | -888.76 Million JPY | -238.336% |
| Stella Pharma Corporation | -723.85 Million JPY | -315.415% |
| TMS Co., Ltd. | -937 Million JPY | -220.918% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | -287.804% |
| Cuorips Inc. | -518 Million JPY | -480.502% |
| K Pharma,Inc. | 366.05 Million JPY | 921.455% |
| Takara Bio Inc. | 8.02 Billion JPY | 137.475% |
| ReproCELL Incorporated | 8.24 Million JPY | 36570.588% |
| PhoenixBio Co., Ltd. | 87.93 Million JPY | 3519.455% |
| StemCell Institute Inc. | 534.35 Million JPY | 662.736% |
| Japan Tissue Engineering Co., Ltd. | 244.81 Million JPY | 1328.279% |
| CellSeed Inc. | -836.51 Million JPY | -259.467% |